PLoS ONE (Jan 2013)

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.

  • Jan Vesterbacka,
  • Piotr Nowak,
  • Babilonia Barqasho,
  • Samir Abdurahman,
  • Jessica Nyström,
  • Staffan Nilsson,
  • Hiroyuki Funaoka,
  • Tatsuo Kanda,
  • Lars-Magnus Andersson,
  • Magnus Gisslèn,
  • Anders Sönnerborg

DOI
https://doi.org/10.1371/journal.pone.0055038
Journal volume & issue
Vol. 8, no. 1
p. e55038

Abstract

Read online

We investigated whether there are differences in the effects on microbial translocation (MT) and enterocyte damage by different antiretroviral therapy (ART) regimens after 1.5 years and whether antibiotic use has impact on MT. In a randomized clinical trial (NCT01445223) on first line ART, patients started either lopinavir/r (LPV/r) (n = 34) or efavirenz (EFV) containing ART (n = 37). Lipopolysaccharide (LPS), sCD14, anti-flagellin antibodies and intestinal fatty acid binding protein (I-FABP) levels were determined in plasma at baseline (BL) and week 72 (w72).The levels of LPS and sCD14 were reduced from BL to w72 (157.5 pg/ml vs. 140.0 pg/ml, p = 0.0003; 3.13 ug/ml vs. 2.85 ug/ml, p = 0.005, respectively). The levels of anti-flagellin antibodies had decreased at w72 (0.35 vs 0.31 [OD]; p<0.0004), although significantly only in the LPV/r arm. I-FABP levels increased at w72 (2.26 ng/ml vs 3.13 ng/ml; p<0.0001), although significantly in EFV treated patients only. Patients given antibiotics at BL had lower sCD14 levels at w72 as revealed by ANCOVA compared to those who did not receive (Δ = -0.47 µg/ml; p = 0.015).Markers of MT and enterocyte damage are elevated in untreated HIV-1 infected patients. Long-term ART reduces the levels, except for I-FABP which role as a marker of MT is questionable in ART-experienced patients. Why the enterocyte damage seems to persist remains to be established. Also antibiotic usage may influence the kinetics of the markers of MT.ClinicalTrials.gov NCT01445223.